Product References
Changes in Tumor Stem Cell Markers and Epithelial-Mesenchymal Transition Markers in Nonluminal Breast Cancer after Neoadjuvant Chemotherapy and Their Correlation with Contrast-Enhanced Ultrasound.
BioMed research international
Leng X,Huang G,Zhang L,Ding J,Ma F
MA5-11833 was used in Western Blotting to investigate the changes in CSC markers and EMT markers after NAC in nonluminal breast cancer and their correlation with contrast-enhanced ultrasound (CEUS) features and chemotherapy efficacy.
Fri May 07 00:00:00 UTC 2021
Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.
Oncology reports
Liao S,Gan L,Qin W,Liu C,Mei Z
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Flow Cytometry
Mon Oct 01 00:00:00 UTC 2018
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature
Shu S,Lin CY,He HH,Witwicki RM,Tabassum DP,Roberts JM,Janiszewska M,Huh SJ,Liang Y,Ryan J,Doherty E,Mohammed H,Guo H,Stover DG,Ekram MB,Brown J,D'Santos C,Krop IE,Dillon D,McKeown M,Ott C,Qi J,Ni M,Rao PK,Duarte M,Wu SY,Chiang CM,Anders L,Young RA,Winer E,Letai A,Barry WT,Carroll JS,Long H,Brown M,Liu XS,Meyer CA,Bradner JE,Polyak K
MA5-11833 was used in immunohistochemistry to study triple-negative breast cancer and BET bromodomain inhibitor response and resistance
Thu Jan 21 00:00:00 UTC 2016
The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer.
Breast cancer (Dove Medical Press)
Isfoss BL,Holmqvist B,Jernström H,Alm P,Olsson H
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Immunofluorescence
Fri Jun 17 00:00:00 UTC 2016
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Human pathology
Davidson B
MA511833 was used in immunohistochemistry - paraffin section to validate CD24 overexpression in high-grade serous carcinoma effusions
Thu Dec 01 00:00:00 UTC 2016
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Oncology letters
Liu YX,Wang KR,Xing H,Zhai XJ,Wang LP,Wang W
MA5-11833 was used in immunohistochemistry - paraffin section to classify triple-negative breast cancer into subtypes
Mon Aug 01 00:00:00 UTC 2016
Membranous CD24 drives the epithelial phenotype of pancreatic cancer.
Oncotarget
Lubeseder-Martellato C,Hidalgo-Sastre A,Hartmann C,Alexandrow K,Kamyabi-Moghaddam Z,Sipos B,Wirth M,Neff F,Reichert M,Heid I,Schneider G,Braren R,Schmid RM,Siveke JT
MA511833 was used in immunohistochemistry - paraffin section to determine the function of CD24 using a mouse model of pancreatic ductal adenocarcinoma and cerulein-induced acute pancreatitis
Tue Aug 02 00:00:00 UTC 2016
Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
PloS one
Horimoto Y,Arakawa A,Sasahara N,Tanabe M,Sai S,Himuro T,Saito M
MA5-11833 was used in immunohistochemistry - paraffin section to propose that CD44+/24- is a good prognostic marker for breast cancer
Tue Jun 20 00:00:00 UTC 2017
Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Breast cancer research and treatment
Oon ML,Thike AA,Tan SY,Tan PH
MA5-11833 was used in immunohistochemistry to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma
Sun Feb 01 00:00:00 UTC 2015
Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer.
Bioorganic & medicinal chemistry
Karakas D,Cevatemre B,Aztopal N,Ari F,Yilmaz VT,Ulukaya E
MA5-11833 was used in flow cytometry to assess the effects of palladium(II) and niclosamide on the Wnt signaling pathway associated with breast cancer stem cells
Tue Sep 01 00:00:00 UTC 2015
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer.
PloS one
Kwon MJ,Han J,Seo JH,Song K,Jeong HM,Choi JS,Kim YJ,Lee SH,Choi YL,Shin YK
MA5-11833 was used in immunohistochemistry to elucidate a poor prognosis in triple-negative breast cancer and luminal A by CD24 overexpression
Wed Jun 01 00:00:00 UTC 2016
Interleukin-6 and pro inflammatory status in the breast tumor microenvironment.
World journal of surgical oncology
Sanguinetti A,Santini D,Bonafè M,Taffurelli M,Avenia N
MA5-11833 was used in immunohistochemistry - paraffin section to study the breast tumor microenvironment and interleukin-6 and pro inflammatory status
Sat Mar 28 00:00:00 UTC 2015
Genetic and phenotypic diversity in breast tumor metastases.
Cancer research
Almendro V,Kim HJ,Cheng YK,Gönen M,Itzkovitz S,Argani P,van Oudenaarden A,Sukumar S,Michor F,Polyak K
MA5-11833 was used in immunohistochemistry to study the diversity of breast cancer metastases at the genetic and phenotypic levels
Sat Mar 01 00:00:00 UTC 2014
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation.
Apoptosis : an international journal on programmed cell death
Wang YC,Wang JL,Kong X,Sun TT,Chen HY,Hong J,Fang JY
MA5-11833 was used in immunohistochemistry to study the role of STAT3 in the mechanism by which CD24 induces gastric carcinogenesis and the progression of gastric cancer
Tue Apr 01 00:00:00 UTC 2014
MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Breast cancer research and treatment
Gwak JM,Kim HJ,Kim EJ,Chung YR,Yun S,Seo AN,Lee HJ,Park SY
MA5-11833 was used in immunohistochemistry - paraffin section to study miR-9, and miR-155 expression in breast cancer and how their expression correlates with different features of breast cancer
Fri Aug 01 00:00:00 UTC 2014
Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Mylona E,Melissaris S,Giannopoulou I,Theohari I,Papadimitriou C,Keramopoulos A,Nakopoulou L
MA5-11833 was used in immunohistochemistry to study the prognostic and clinical value of the Y-box-binding protein-1 expression pattern in breast carcinoma patients
Sat Mar 01 00:00:00 UTC 2014
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Journal of molecular histology
Adamczyk A,Niemiec JA,Ambicka A,Mucha-Małecka A,Mituś J,Ryś J
MA5-11833 was used in immunohistochemistry to study the prognostic and clinical significance of CD44/CD24 expression in node-positive invasive ductal breast cancer
Sat Feb 01 00:00:00 UTC 2014
CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Clinical breast cancer
Zhou X
MA5-11833 was used in immunohistochemistry to study the whether there is a relationship between pathologic complete response in breast cancer patients receieving neoadjuvant chemotherapy and CD24 polymorphisms
Tue Apr 01 00:00:00 UTC 2014
Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy.
Urologic oncology
Hofner T,Macher-Goeppinger S,Klein C,Schillert A,Eisen C,Wagner S,Rigo-Watermeier T,Baccelli I,Vogel V,Trumpp A,Sprick MR
MA5-11833 was used in immunohistochemistry to study the expression of the cancer stem cell markers CD24 abd CD44 in urothelial bladder cancer and their utility in prognosis and in predicting radical cystectomy outcome
Tue Jul 01 00:00:00 UTC 2014
Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
BMC cancer
Mizukami T,Kamachi H,Mitsuhashi T,Tsuruga Y,Hatanaka Y,Kamiyama T,Matsuno Y,Taketomi A
MA5-11833 was used in immunohistochemistry - paraffin section to investigate the effect of neoadjuvant chemoradiotherapy on pancreatic adenocarcinoma cancer stem cell markers
Sun Sep 21 00:00:00 UTC 2014
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Oncotarget
Gasparini P,Cascione L,Fassan M,Lovat F,Guler G,Balci S,Irkkan C,Morrison C,Croce CM,Shapiro CL,Huebner K
MA5-11833 was used in immunohistochemistry to study the prognostic and predictive value of a four miRNA expression signature in triple-negative breast cancer
Sat Mar 15 00:00:00 UTC 2014
Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.
Cancer science
Ohara Y,Oda T,Sugano M,Hashimoto S,Enomoto T,Yamada K,Akashi Y,Miyamoto R,Kobayashi A,Fukunaga K,Morishita Y,Ohkohchi N
MA5-11833 was used in immunohistochemistry to study the clinical significance of CD44(+)/CD24(+)/EpCAM(+) cells in pancreatic cancer
Thu Aug 01 00:00:00 UTC 2013
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
World journal of gastroenterology
Kim K,Min HS,Chie EK,Jang JY,Kim SW,Han SW,Oh DY,Im SA,Kim TY,Bang YJ,Jang JJ,Ha SW
MA5-11833 was used in immunohistochemistry to study the utility of CD24 expression for predicting distant metastasis in extrahepatic bile duct cancer
Thu Mar 07 00:00:00 UTC 2013
Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Huang LW,Lee CC
MA5-11833 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expresson of CD24 in patients with cervical carcinoma
Fri Feb 01 00:00:00 UTC 2013
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Breast cancer research and treatment
Bane A,Viloria-Petit A,Pinnaduwage D,Mulligan AM,O'Malley FP,Andrulis IL
MA5-11833 was used in immunohistochemistry to study the expression of cancer stem cell markers in familial breast cancer and the clinical significance
Mon Jul 01 00:00:00 UTC 2013
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma.
Journal of clinical pathology
Pinato DJ,Nya P,Sharma R,Mauri FA
MA5-11833 was used in immunohistochemistry to study the diagnostic value of CD24 for differentiating between malignant mesothelioma and pulmonary adenocarcinoma
Fri Mar 01 00:00:00 UTC 2013
Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Pancreas
Kang MJ,Lee KB,Jang JY,Kwon W,Park JW,Chang YR,Kim SW
MA5-11833 was used in immunohistochemistry to study the wide disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma
Fri Nov 01 00:00:00 UTC 2013
Histological study of stem-like cells in human colon adenocarcinoma at different stages of the disease.
Biotechnic & histochemistry : official publication of the Biological Stain Commission
Florianova L,Orain M,Têtu B,Doillon CJ
MA5-11833 was used in immunohistochemistry to study the presence of stem-like cells at different stages of human colon adenocarcinoma
Mon Jul 01 00:00:00 UTC 2013
Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
PloS one
Wu Y,Sarkissyan M,Elshimali Y,Vadgama JV
MA5-11833 was used in immunohistochemistry to study the prevalence of the high CD44(+)/low CD24(+) coupled with PTEN loss phenotype of triple-nagative breast cancer of African-American and Hispanic/Latina women in an Amercican population
Wed May 28 00:00:00 UTC 2014
CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.
Diagnostic pathology
Soave DF,Oliveira da Costa JP,da Silveira GG,Ianez RC,de Oliveira LR,Lourenço SV,Ribeiro-Silva A
MA5-11833 was used in immunohistochemistry to study the potential prognostic value of immunohistochemical expression of CD44/CD24 in salivary gland malignant neoplasms
Mon Feb 18 00:00:00 UTC 2013
Stem cell-related markers in primary breast cancers and associated metastatic lesions.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Guler G,Balci S,Costinean S,Ussakli CH,Irkkan C,Suren D,Sari E,Altundag K,Ozisik Y,Jones S,Bacher J,Shapiro CL,Huebner K
MA5-11833 was used in immunohistochemistry - paraffin section to determine if stem cell subpopulations are more frequent in metastatic than in primary tumors
Sun Jul 01 00:00:00 UTC 2012
Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.
Histopathology
Isfoss BL,Holmqvist B,Alm P,Olsson H
MA5-11833 was used in immunocytochemistry to study the distribution of ALDH1-positive stem cells in benign breast tissue of women with and without breast cancer
Thu Mar 01 00:00:00 UTC 2012
Expression of adhesion, attachment and invasion markers in eutopic and ectopic endometrium: a link to the aetiology of endometriosis.
Human reproduction (Oxford, England)
Sundqvist J,Andersson KL,Scarselli G,Gemzell-Danielsson K,Lalitkumar PG
MA5-11833 was used in immunohistochemistry to study the significance for the development of endometriosis of the expression of adhesion, attachment and invasion molecules by eutopic and ectopic endometrium
Sat Sep 01 00:00:00 UTC 2012
Identification of prognostic biomarkers for glioblastomas using protein expression profiling.
International journal of oncology
Jung Y,Joo KM,Seong DH,Choi YL,Kong DS,Kim Y,Kim MH,Jin J,Suh YL,Seol HJ,Shin CS,Lee JI,Kim JH,Song SY,Nam DH
MA5-11833 was used in immunohistochemistry - paraffin section to identify diagnostic and prognostic markers for glioblastoma
Sun Apr 01 00:00:00 UTC 2012
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
Stem cells (Dayton, Ohio)
Vieira AF,Ricardo S,Ablett MP,Dionísio MR,Mendes N,Albergaria A,Farnie G,Gerhard R,Cameselle-Teijeiro JF,Seruca R,Schmitt F,Clarke RB,Paredes J
MA5-11833 was used in immunohistochemistry to study the role of P-cadherin in mediating basal-like breast cancer stem cell properties
Tue May 01 00:00:00 UTC 2012
Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expression.
Breast (Edinburgh, Scotland)
Simonetti S,Terracciano L,Zlobec I,Kilic E,Stasio L,Quarto M,Pettinato G,Insabato L
MA5-11833 was used in immunohistochemistry to study the immunohistology of CD24 and CD44 isoforms in invasive micropapillary carcinoma of the breast
Sun Apr 01 00:00:00 UTC 2012
Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Breast (Edinburgh, Scotland)
Gerhard R,Ricardo S,Albergaria A,Gomes M,Silva AR,Logullo ÂF,Cameselle-Teijeiro JF,Paredes J,Schmitt F
MA5-11833 was used in immunohistochemistry to study the immunohistochemical expression of claudins in metaplastic breast carcinomas
Fri Jun 01 00:00:00 UTC 2012
Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.
Medical oncology (Northwood, London, England)
Wang H,Wang W,Wang X,Cai K,Wu H,Ju Q,Huang Z,Gao X
MA5-11833 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expression of NDRG2 and CD24 in patients with lung adenocarcinoma
Sat Dec 01 00:00:00 UTC 2012
Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Oncology
Hashimoto K,Shimizu C,Tsuda H,Saji S,Osaki A,Shigekawa T,Aogi K
MA5-11833 was used in immunohistochemistry to study the role of breast cancer stem cells in the response of hormone receptor-positive breast cancer to endocrine therapy
Thu Jun 21 00:00:00 UTC 2012
Clinical value of CD24 expression in retinoblastoma.
Journal of biomedicine & biotechnology
Li J,Li C,Yuan H,Gong F
MA5-11833 was used in immunohistochemistry to study the relationship between CD24 expression and clinocopathology in retinoblastoma
Mon Jan 07 00:00:00 UTC 2013
Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery.
Radiation oncology journal
Koh HK,Park HJ,Kim K,Chie EK,Min HS,Ha SW
MA5-11833 was used in immunohistochemistry to attempt to identify prognostic biomarkers for extraheptic bile duct cancer
Sat Dec 01 00:00:00 UTC 2012
CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Journal of experimental & clinical cancer research : CR
Lin Y,Zhong Y,Guan H,Zhang X,Sun Q
MA5-11833 was used in immunohistochemistry to study the prognostic value of CD44(+)/CD24(-) cells in invasive ductal carcinoma following surgical resection and chemotherapy
Wed Jul 04 00:00:00 UTC 2012
In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
PloS one
Perrone G,Gaeta LM,Zagami M,Nasorri F,Coppola R,Borzomati D,Bartolozzi F,Altomare V,Trodella L,Tonini G,Santini D,Cavani A,Muda AO
MA5-11833 was used in immunohistochemistry to develop methods for the routine detection of CD44(+)/CD24(-) cells in breast cancer samples obtained at surgery
Tue Mar 19 00:00:00 UTC 2013
CD24 expression as a marker for predicting clinical outcome in human gliomas.
Journal of biomedicine & biotechnology
Deng J,Gao G,Wang L,Wang T,Yu J,Zhao Z
MA5-11833 was used in immunohistochemistry to study the prognostic value of CD24 expression in human gliomas
Fri Sep 07 00:00:00 UTC 2012
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
The Journal of clinical investigation
Marotta LL,Almendro V,Marusyk A,Shipitsin M,Schemme J,Walker SR,Bloushtain-Qimron N,Kim JJ,Choudhury SA,Maruyama R,Wu Z,Gönen M,Mulvey LA,Bessarabova MO,Huh SJ,Silver SJ,Kim SY,Park SY,Lee HE,Anderson KS,Richardson AL,Nikolskaya T,Nikolsky Y,Liu XS,Root DE,Hahn WC,Frank DA,Polyak K
MA5-11833 was used in immunocytochemistry to identify treatment targets common to breast tumor subpopulations
Fri Jul 01 00:00:00 UTC 2011
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.
Cancer research
Damelin M,Geles KG,Follettie MT,Yuan P,Baxter M,Golas J,DiJoseph JF,Karnoub M,Huang S,Diesl V,Behrens C,Choe SE,Rios C,Gruzas J,Sridharan L,Dougher M,Kunz A,Hamann PR,Evans D,Armellino D,Khandke K,Marquette K,Tchistiakova L,Boghaert ER,Abraham RT,Wistuba II,Zhou BB
MA5-11833 was used in immunohistochemistry to investigate the heterogeneity and hierarchy in non-small cell lung cancer cells
Wed Jun 15 00:00:00 UTC 2011
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
British journal of cancer
Lee HE,Kim JH,Kim YJ,Choi SY,Kim SW,Kang E,Chung IY,Kim IA,Kim EJ,Choi Y,Ryu HS,Park SY
MA5-11833 was used in immunohistochemistry to study the increase in cancer stem cell numbers after primary systemic therapy as a poor prognostic factor in breast cancer
Tue May 24 00:00:00 UTC 2011
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Journal of clinical pathology
Ricardo S,Vieira AF,Gerhard R,Leitão D,Pinto R,Cameselle-Teijeiro JF,Milanezi F,Schmitt F,Paredes J
MA5-11833 was used in immunohistochemistry to study the expression of breast cancer stem cell markers
Tue Nov 01 00:00:00 UTC 2011
CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Ultrastructural pathology
Lü X,Xu K,Lü H,Yin Y,Ma C,Liu Y,Li H,Suo Z
MA5-11833 was used in immunohistochemistry to investigate the role of CD44+/CD24- cells in breast carcinomas
Fri Apr 01 00:00:00 UTC 2011
Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.
Applied immunohistochemistry & molecular morphology : AIMM
Balic M,Rapp N,Stanzer S,Lin H,Strutz J,Szkandera J,Daidone MG,Samonigg H,Cote RJ,Dandachi N
MA5-11833 was used in immunohistochemistry to investigate the efficiency of a new method for the assessment of putative disseminating breast cancer stem cells
Sat Jan 01 00:00:00 UTC 2011
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.
The Journal of clinical investigation
Park SY,Gönen M,Kim HJ,Michor F,Polyak K
MA5-11833 was used in immunohistochemistry to identify the sources of genetic diversity in human breast tumors
Mon Feb 01 00:00:00 UTC 2010
CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation.
Inflammatory bowel diseases
Ahmed MA,Jackson D,Seth R,Robins A,Lobo DN,Tomlinson IP,Ilyas M
MA5-11833 was used in immunohistochemistry to investigate the role of CD24 in inflammatory bowel disease, cell motility and colony formation
Sat May 01 00:00:00 UTC 2010
Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Sung CO,Park W,Choi YL,Ahn G,Song SY,Huh SJ,Bae DS,Kim BG,Lee JH
MA5-11833 was used in immunohistochemistry to investigate the prognostic value of CD24 in the radical hysterectomy and radiotherapy for cervical squamous cell carcinoma
Tue Jun 01 00:00:00 UTC 2010
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Molecular cancer therapeutics
Rajeshkumar NV,Rasheed ZA,García-García E,López-Ríos F,Fujiwara K,Matsui WH,Hidalgo M
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Flow Cytometry
Wed Sep 01 00:00:00 UTC 2010
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Molecular cancer therapeutics
Rajeshkumar NV,Rasheed ZA,García-García E,López-Ríos F,Fujiwara K,Matsui WH,Hidalgo M
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Flow Cytometry
Wed Sep 01 00:00:00 UTC 2010
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients.
World journal of gastroenterology
Hostettler L,Zlobec I,Terracciano L,Lugli A
MA5-11833 was used in immunohistochemistry to study the prognostic value of 8 putative cancer stem cell markers in colorectal cancer
Sun Feb 14 00:00:00 UTC 2010
CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.
Pathology oncology research : POR
Bektas S,Bahadir B,Ucan BH,Ozdamar SO
MA5-11833 was used in immunohistochemistry to study the clinicopathologic significance of CD24 and galectin-1 expression in gastric adenocarcinoma
Wed Dec 01 00:00:00 UTC 2010
Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin.
Pathology international
Kawasaki H,Ogura H,Arai Y,Baba S,Kosugi I,Tsutsui Y,Iwashita T
MA5-11833 was used in immunohistochemistry to investigate the stem-like characteristics of microscopic pulmonary emboli
Mon Mar 01 00:00:00 UTC 2010
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Clinical cancer research : an official journal of the American Association for Cancer Research
Yang XR,Xu Y,Yu B,Zhou J,Li JC,Qiu SJ,Shi YH,Wang XY,Dai Z,Shi GM,Wu B,Wu LM,Yang GH,Zhang BH,Qin WX,Fan J
MA5-11833 was used in immunohistochemistry to study the role of CD24 in tumor invasion and its prognostic significance in hepatocellular carcinoma
Tue Sep 01 00:00:00 UTC 2009
CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
Annals of surgical oncology
Sano A,Kato H,Sakurai S,Sakai M,Tanaka N,Inose T,Saito K,Sohda M,Nakajima M,Nakajima T,Kuwano H
MA5-11833 was used in immunohistochemistry to study the prognostic value of CD24 overexpression in esophageal squamous cell carcinoma
Sun Feb 01 00:00:00 UTC 2009
Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium.
Histology and histopathology
Kim KH,Choi JS,Kim JM,Choi YL,Shin YK,Lee HC,Seong IO,Kim BK,Chae SW,Kim SH
MA5-11833 was used in immunohistochemistry to investigate the distribution of CD24 in normal and pathologic endometrium
Sun Mar 01 00:00:00 UTC 2009
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Proceedings of the National Academy of Sciences of the United States of America
Horwitz KB,Dye WW,Harrell JC,Kabos P,Sartorius CA
MA5-11833 was used in immunohistochemistry to study rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast tumors
Tue Apr 15 00:00:00 UTC 2008
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Breast cancer research : BCR
Honeth G,Bendahl PO,Ringnér M,Saal LH,Gruvberger-Saal SK,Lövgren K,Grabau D,Fernö M,Borg A,Hegardt C
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Immunohistochemistry
Wed Nov 12 00:00:00 UTC 2008
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Breast cancer research : BCR
Honeth G,Bendahl PO,Ringnér M,Saal LH,Gruvberger-Saal SK,Lövgren K,Grabau D,Fernö M,Borg A,Hegardt C
Published figure using CD24 monoclonal antibody (Product # MA5-11833) in Immunohistochemistry
Wed Nov 12 00:00:00 UTC 2008
The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
Human pathology
Mylona E,Giannopoulou I,Fasomytakis E,Nomikos A,Magkou C,Bakarakos P,Nakopoulou L
MA5-11833 was used in immunohistochemistry to study the prognostic importance of CD44(+)/CD24(-/low) and CD44(-)/CD24(+) tumor phenotypes in invasive breast carcinoma
Tue Jul 01 00:00:00 UTC 2008
CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Virchows Archiv : an international journal of pathology
Winkler A,Zigeuner R,Rehak P,Hutterer G,Chromecki T,Langner C
MA5-11833 was used in immunohistochemistry to study the correlation of CD24 expression with tumor progression in urothelial carcinoma of the upper urinary tract
Mon Jan 01 00:00:00 UTC 2007
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Clinical cancer research : an official journal of the American Association for Cancer Research
Balic M,Lin H,Young L,Hawes D,Giuliano A,McNamara G,Datar RH,Cote RJ
MA5-11833 was used in immunohistochemistry to characterize the early disseminated cancer cells in bone marrow of breast cancer patients
Sun Oct 01 00:00:00 UTC 2006
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
Clinical cancer research : an official journal of the American Association for Cancer Research
Weichert W,Denkert C,Burkhardt M,Gansukh T,Bellach J,Altevogt P,Dietel M,Kristiansen G
MA5-11833 was used in immunohistochemistry to study the prognostic value of cytoplasmic CD24 expression in colorectal cancer
Thu Sep 15 00:00:00 UTC 2005
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
The Journal of pathology
Kristiansen G,Pilarsky C,Wissmann C,Kaiser S,Bruemmendorf T,Roepcke S,Dahl E,Hinzmann B,Specht T,Pervan J,Stephan C,Loening S,Dietel M,Rosenthal A
MA5-11833 was used in immunohistochemistry to profile the expression patterns of microdissected prostate cancer samples to identify new prognostic markers
Tue Feb 01 00:00:00 UTC 2005
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
The Prostate
Kristiansen G,Pilarsky C,Pervan J,Stürzebecher B,Stephan C,Jung K,Loening S,Rosenthal A,Dietel M
MA5-11833 was used in immunohistochemistry to study the prognostic value of CD24 expression in low grade or organ confined prostate cancer
Sun Feb 01 00:00:00 UTC 2004
CD24 expression is a new prognostic marker in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Kristiansen G,Winzer KJ,Mayordomo E,Bellach J,Schlüns K,Denkert C,Dahl E,Pilarsky C,Altevogt P,Guski H,Dietel M
MA5-11833 was used in immunohistochemistry to study CD24 expression as a prognostic marker in breast cancer.
Wed Oct 15 00:00:00 UTC 2003
